8-K
filed February 7, 2023, 6:59 PM ET
ticker USNA
CIK 0000896264
earnings
confidence high
sentiment negative
materiality 0.75
USANA Q4 net sales $228M (-15% YoY), EPS $0.66 (-36%); FY2023 guidance reiterated
USANA HEALTH SCIENCES INC
2022-FY EPS reported
$3.59
revenue$998,601,000
- Q4 net sales $228M, down 15% YoY; diluted EPS $0.66, down 36% YoY.
- FY2022 net sales $999M (-16% YoY), EPS $3.59 (-37%); operating cash flow $104M.
- Active customers 490,000, down 13% YoY but up 3% sequentially; key markets stabilized.
- FY2023 outlook: net sales $850M-$950M, diluted EPS $2.35-$3.30; wide range on China uncertainty.
- Ended with $288M cash, debt-free; $83M share buyback remaining; no Q4 repurchases.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
USANA HEALTH SCIENCES INC reported fiscal year 2023 results: revenue $850 million to $950 million, EPS $2.35 to $3.30. Guidance reaffirmed.
- Period
- fiscal year 2023
- Revenue
- $850 million to $950 million
- EPS
- $2.35 to $3.30
- Guidance
- reaffirmed
- Result
- guidance update
Exact text from the filing
Company reiterates fiscal year 2023 net sales and diluted EPS outlook of $850 million to $950 million and $2.35 to $3.30, respectively.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
USANA HEALTH SCIENCES INC reported fiscal year ended December 31, 2022 results: revenue $999 million, EPS $3.59. Guidance reaffirmed.
- Period
- fiscal year ended December 31, 2022
- Revenue
- $999 million
- EPS
- $3.59
- Guidance
- reaffirmed
- Result
- reported results
Exact text from the filing
Fiscal year 2022 net sales were $999 million as compared with $1,186 million during fiscal year 2021. Fiscal year 2022 diluted EPS totaled $3.59 versus $5.73 during fiscal year 2021.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
USANA HEALTH SCIENCES INC reported fourth quarter ended December 31, 2022 results: revenue $228 million, EPS $0.66. Guidance reaffirmed.
- Period
- fourth quarter ended December 31, 2022
- Revenue
- $228 million
- EPS
- $0.66
- Guidance
- reaffirmed
- Result
- reported results
Exact text from the filing
Fourth quarter net sales were $228 million versus $267 million during the prior-year period. Fourth quarter diluted EPS was $0.66 as compared with $1.03 during Q4 2021.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.